258.38
3.11 (1.22%)
Penutupan Terdahulu | 255.27 |
Buka | 255.85 |
Jumlah Dagangan | 467,691 |
Purata Dagangan (3B) | 520,406 |
Modal Pasaran | 10,005,998,592 |
Harga / Pendapatan (P/E TTM) | 237.05 |
Harga / Pendapatan (P/E Ke hadapan) | 83.33 |
Harga / Jualan (P/S) | 9.39 |
Harga / Buku (P/B) | 9.48 |
Julat 52 Minggu | |
Tarikh Pendapatan | 28 Jul 2025 - 1 Aug 2025 |
Margin Keuntungan | 3.41% |
Margin Operasi (TTM) | 12.45% |
EPS Cair (TTM) | 1.08 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 16.30% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 256.50% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 18.19% |
Nisbah Semasa (MRQ) | 6.30 |
Aliran Tunai Operasi (OCF TTM) | 179.16 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 135.83 M |
Pulangan Atas Aset (ROA TTM) | 5.82% |
Pulangan Atas Ekuiti (ROE TTM) | 3.50% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Menurun | Bercampur |
Medical Devices (Global) | Menurun | Bercampur | |
Stok | Penumbra, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -0.5 |
Purata | 1.75 |
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 3.46% |
% Dimiliki oleh Institusi | 91.80% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 330.00 (RBC Capital, 27.72%) | Beli |
330.00 (UBS, 27.72%) | Beli | |
330.00 (Truist Securities, 27.72%) | Beli | |
Median | 327.50 (26.75%) | |
Rendah | 315.00 (Wells Fargo, 21.91%) | Beli |
Purata | 324.67 (25.66%) | |
Jumlah | 6 Beli | |
Harga Purata @ Panggilan | 298.25 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Baird | 24 Apr 2025 | 325.00 (25.78%) | Beli | 298.25 |
RBC Capital | 24 Apr 2025 | 330.00 (27.72%) | Beli | 298.25 |
Stifel | 24 Apr 2025 | 318.00 (23.07%) | Beli | 298.25 |
Truist Securities | 24 Apr 2025 | 330.00 (27.72%) | Beli | 298.25 |
11 Apr 2025 | 315.00 (21.91%) | Beli | 272.32 | |
UBS | 24 Apr 2025 | 330.00 (27.72%) | Beli | 298.25 |
Wells Fargo | 24 Apr 2025 | 315.00 (21.91%) | Beli | 298.25 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
05 Jun 2025 | Pengumuman | Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization |
20 May 2025 | Pengumuman | Penumbra, Inc. to Present at Upcoming Investor Conferences |
29 Apr 2025 | Pengumuman | Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference |
23 Apr 2025 | Pengumuman | Penumbra, Inc. Reports First Quarter 2025 Financial Results |
03 Apr 2025 | Pengumuman | Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 |
02 Apr 2025 | Pengumuman | Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |